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Background: Past experience and modelling suggest that, in most cases, mass treatment strategies are not likely to
succeed in interrupting Plasmodium falciparum malaria transmission. However, this does not preclude their use to
reduce disease burden. Mass screening and treatment (MSAT) is preferred to mass drug administration (MDA), as
the latter involves massive over-use of drugs. This paper reports simulations of the incremental cost-effectiveness of
well-conducted MSAT campaigns as a strategy for P. falciparum malaria disease-burden reduction in settings with
varying receptivity (ability of the combined vector population in a setting to transmit disease) and access to case
management.
Methods: MSAT incremental cost-effectiveness ratios (ICERs) were estimated in different sub-Saharan African settings
using simulation models of the dynamics of malaria and a literature-based MSAT cost estimate. Imported infections were
simulated at a rate of two per 1,000 population per annum. These estimates were compared to the ICERs of scaling up
case management or insecticide-treated net (ITN) coverage in each baseline health system, in the absence of MSAT.
Results: MSAT averted most episodes, and resulted in the lowest ICERs, in settings with a moderate level of disease
burden. At a low pre-intervention entomological inoculation rate (EIR) of two infectious bites per adult per annum
(IBPAPA) MSAT was never more cost-effective than scaling up ITNs or case management coverage. However, at
pre-intervention entomological inoculation rates (EIRs) of 20 and 50 IBPAPA and ITN coverage levels of 40 or 60%,
respectively, the ICER of MSAT was similar to that of scaling up ITN coverage further.
Conclusions: In all the transmission settings considered, achieving a minimal level of ITN coverage is a “best buy”. At
low transmission, MSAT probably is not worth considering. Instead, MSAT may be suitable at medium to high levels of
transmission and at moderate ITN coverage. If undertaken as a burden-reducing intervention, MSAT should be
continued indefinitely and should complement, not replace, case management and vector control interventions.
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Mass drug administration (MDA), where the entire
population is treated with anti-malarial drugs, was tried
on a number of occasions during the malaria eradication
efforts of the last century, and sporadically since then.
Mass screening and treatment (MSAT), which involves
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reproduction in any medium, provided the ortreating those who test positive, has not been empirically
tested, although an upcoming clinical trial in Burkina
Faso aims to evaluate it [1]. Another variant proposed is
“focal screening and treatment”, which involves screen-
ing all people living in a defined geographical area [2].
This approach is now being used in an attempt to con-
tain emerging artemisinin-resistant falciparum malaria
in western Cambodia [3].
Unfortunately, MDA has proved disappointing in most
instances for the objective of interrupting transmission.
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undertook MDA with varying frequencies and numbers
of rounds [4]. The authors found that MDA has almost
always failed to interrupt transmission, although it often
led to a marked reduction in parasite prevalence and
probably a transient effect on malaria-related morbidity
and mortality. The authors concluded that direct MDA
with a full therapeutic drug dose might have a role to
play in circumstances such as the control of epidemics,
or in relatively low transmission areas or in those with a
short transmission season. However, it is not likely to
have a sustained effect in most malaria-endemic areas.
These discouraging findings are echoed by several recent
model-based investigations of MDA and MSAT. Mathem-
atical malaria transmission models are useful tools to
synthesize data and make predictions about intervention
impact where trials are not feasible. One study found that
only in areas with low transmission of less than 10 infec-
tious bites per adult per annum (IBPAPA) could parasite
prevalence be reduced to less than one percent with an-
nual MSAT and insecticide-treated nets (ITNs) at 80%
coverage [5]. Additional investigations of the impact of
MDA and MSAT using different drugs, at different tim-
ings, and with correlation in probability of participating in
successive rounds, in varying initial endemicity settings,
were undertaken using a similar model [6]. Transmission
was found to rebound to previous levels within about two
years after one round of the intervention in a low-
endemicity setting. However, repeating the intervention or
combining it with vector control enhanced and extended
the impact.
Even if it could be achieved, a major challenge to main-
taining local transmission interruption would be the im-
portation of Plasmodium falciparum infections. Human
populations are connected to each other, and as long as
local vectors have sufficient capacity to transmit malaria,
local transmission can be sustained or re-introduced
through immigration of infected people or infective mos-
quitoes. A recent modelling study [7] found that, even at
relatively low receptivity levels, case management alone
could not reliably prevent P. falciparum transmission re-
establishment in the face of medium to high importation
rates. These findings suggest that achieving and maintain-
ing local transmission interruption without large-scale
vector control across most of sub-Saharan Africa will be
difficult for the foreseeable future.
Although MDA or MSAT rounds can be expected to
have only an ephemeral effect on prevalence, it may be a
viable strategy to reduce malaria disease burden if car-
ried out regularly. Intermittent preventive treatment in
pregnant women, children and infants are targeted, con-
tinuous MDA forms that have been found to reduce bur-
den in specific population groups [8,9]. To evaluate the
potential role of MDA or MSAT for burden reduction, itis important to consider both the expected effectiveness
and intervention cost.
The effectiveness of both MDA and MSAT strategies
may be compromised by the difficulty of achieving suffi-
cient coverage due to refusal of populations to participate
in repeated screenings and/or treatments and population
movements. A further disadvantage of MSAT is that sub-
patent parasitaemia will be missed, and if this contributes
significantly to the infectious reservoir, the intervention ef-
fect will be limited. Experience indicates that the success
of these approaches is predicated on the ability to deploy
them multiple times at high coverage levels and together
with vector control measures [2]. Mass treatment is
thought likely to be more effective if introduced following
reductions in transmission due to other interventions,
such as distribution of ITNs and indoor residual spraying
(IRS) [10].
Due to concerns about the potential for MDA to con-
tribute to the spread of drug resistance [4], MSAT is cur-
rently preferred to MDA, as it avoids the massive over-use
of drugs [11]. However, it is bound to be more difficult and
costly to organize and implement than MDA. There is no
known evaluation to date of the possible cost-effectiveness
of MSAT for reducing malaria disease burden.
This paper’s objective is to predict the incremental cost-
effectiveness of well-conducted MSAT campaigns as a
strategy for P. falciparum malaria disease-burden reduc-
tion in sub-Saharan African settings with varying receptiv-
ity (ability of the combined vector population in a setting
to transmit disease) and access to case management, com-
pared to the same setting in the absence of MSAT.
Methods
Simulation model
A dynamic, individual-based, stochastic model of malaria
biology and epidemiology was used. The model corre-
sponds to the base model in an ensemble of stochastic
simulation models that has been developed recently [12].
Briefly, a simulated human population was updated at
each five-day time step via model components repre-
senting new infections, parasite densities, acquired im-
munity, uncomplicated and severe episodes, direct and
indirect malaria mortality, infectiousness to mosquitoes,
and case management. Simulated immunity to asexual
parasites, derived from cumulative exposure to both in-
oculations and blood stage parasites and transferred ma-
ternal immunity, acted mainly by controlling parasite
densities [13]. The probability of a clinical malaria attack
in a simulated individual depended on the current pa-
rasite density and a pyrogenic threshold [14]. Severe
malaria comprised two episode categories: those that
occurred as a result of overwhelming parasite densities,
and those that arose when an uncomplicated malaria epi-
sode coincided with non-malaria co-morbidity. Mortality
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direct (uncomplicated malaria in conjunction with co-
morbidity, or during the neonatal period as a result of
maternal infection) [15]. Malaria dynamics in mosquitoes
was also modelled [16,17].Transmission settings
The vectorial capacity, or receptivity, is the ability of the
combined vector population in a setting to transmit dis-
ease, expressed as the potential number of inoculations
per time unit originating from one infective person with
no prior immunity. A setting has a baseline vectorial
capacity, which can be altered by interventions under-
taken by the health system, such as vector control. The
effectiveness of MDA and MSAT in terms of burden
reduction is likely related to the actual vectorial cap-
acity (the baseline modified by interventions), which
co-determines, together with immunity, the parasit-
aemia prevalence in the population and the proportion
of asymptomatic infections. An infected individual with
lower immunity is more likely to show clinical symp-
toms and thus, given access to appropriate care, to be
treated promptly by the health system, reducing the
parasite reservoir to be addressed by MSAT.
The pre-intervention entomological inoculation rate
(EIR) was used as a good proxy for the baseline receptiv-
ity. Three pre-intervention EIRs of two, 20 and 50
IBPAPA were simulated, with a seasonality pattern as
observed in Namawala, Tanzania [18]. These EIRs cor-
respond to parasite prevalence in children under five
years of age of approximately 16%, 50%, and 62% [13].
The infection status and immune status at the start of
the simulation were determined by exposing the simu-
lated population to the same annually recurring pattern
of inoculations for a lifetime-long burn-in at the start.
The case management coverage level was set at zero
during the burn-in period in all simulations in order to
ensure that the fitted vectorial capacity was the same
across all scenarios. Case management coverage was
changed to the appropriate level at the beginning of the
main simulation.
ITNs were distributed at 40%, 60% or 80% population
coverage at the beginning of years 1, 4, 7 and 10.
Imported infections were assigned to individuals in the
population via a Poisson process every 30 days at a con-
stant average rate of two imported infections per 1,000
population per year throughout the simulation period.
This rate was chosen because it is on the lower end of
the infection importation rate range (two to eight infec-
tions per 1,000 inhabitants per annum in 2008) esti-
mated in Zanzibar, one of the few places from which
preliminary data are available [19,20]. No infected mos-
quitoes were imported.Case management models
The effectiveness of MSAT is probably related to case
management coverage, which determines the proportion
of symptomatic infections that gets treated. The case
management component [21] models a health system
using artemether-lumefantrine (AL), an artemisinin-based
combination therapy (ACT), as treatment for uncompli-
cated malaria. Individuals with uncomplicated malaria
fevers were assigned a probability of accessing treatment
over the next five-day period of 20, 35 or 55%. These
probabilities were constant over the entire simulation
period. They represent the fever treatment-seeking behav-
iour range recorded in children under five years of age,
using 14-day recall, in nationally representative surveys
conducted in malaria endemic countries in sub-Saharan
Africa [22,23], converted to five-day probabilities for use
in the model. Compliance to the treatment regimen was
set at 90% [24], and the drug was assumed to be 85% ef-
fective [25]. In patients who did not comply with the full
regimen, the drug was assumed to have 20% effectiveness
[26]. All severe cases were assigned a 48% probability of
receiving treatment as an in-patient [27], and parasites
were cleared in all hospitalized cases who survived.
Infectivity of hosts to mosquitoes at a given time point
was modelled as a function of asexual parasite densities
10, 15 and 20 days previously, allowing for a delay
resulting from the time course of gametocytaemia [28].
Effective treatment completely cleared parasites by the
next time step, ending the infection, while ineffective
treatment had no impact on asexual parasite densities.
By clearing asexual parasites, treatment rendered indivi-
duals un-infectious to vectors at later time points. Given
sufficiently high treatment coverage, this lowered infec-
tivity translated into a reduction in EIR. Neither drug
treatment effects on gametocytaemia nor prophylactic
drug effects were modelled, but as AL has a relatively
short half-life, and few treatments were given after the first
MSAT round, this is likely to be of limited consequence.
MSAT timing, coverage and compliance
Five different timings for MSAT were simulated, accord-
ing to the seasonal transmission pattern – at the month
before the peak of EIR, at the peak of EIR, at the month
before the trough of EIR, at the trough of EIR, and at the
month after the trough of EIR. The intervention was con-
ducted annually in years 5 to 12, for a total of eight
rounds. In the base case, MSAT was applied at 85% cove-
rage, which is the level that was achieved in a well-
conducted mass drug administration for malaria in the
Gambia [29]. ACT was given simultaneously to all indivi-
duals with a level of parasitaemia at or above 40 parasites/
μl. A detection limit of 40 parasites per μl corresponds to
the nominal value for standard microscope procedures
that count parasites against 200 leukocytes, assuming a
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rapid diagnostic tests (RDTs) were assumed to have about
the same level of detection as microscopy. All those who
were screened and tested positive by RDT took the drug
and complied fully with the regimen, while none of those
who tested negative took the drug. Correlation among
individuals in participation in different MSAT rounds was
not considered.
The optimal day of the calendar year to conduct an
MSAT campaign was defined as the one, among the days
considered, which minimized the number of episodes
from the beginning of the intervention year to the end of
the simulation period. This occurred one month before
the trough in transmission, defined as the lowest EIR, con-
sistent with other modelling studies [5]. This timing was
used to evaluate the MSAT cost-effectiveness in settings of
varying baseline receptivity, ITN and case management
coverage.
All scenarios had a population size of 100,000, with
underlying demography based on East African life tables
[30], and were run 10 times, each time with a different
seed for the random number generator.
Estimating the cost of MSAT
Methods used to estimate the cost per person screened
are described in detail in supplementary information
(see Additional file 1).
For costing purposes, MSAT was assumed to be con-
ducted through house-to-house visits by village volunteers
or community health workers (CHWs). Two situations
were considered: 1) a village of 1,000 inhabitants where a
cadre of CHWs, trained to manage fever presumptively,
existed and 2) a similar village where volunteers were
newly selected from the local population and had no pre-
vious training or experience with managing illness. In situ-
ation 2, the MSAT-attributable costs of selecting and
training village volunteers for the MSAT intervention may
be lower if the volunteers proceed to take on roles beyond
that of the MSAT intervention; however, this was not
considered
The marginal cost consists of the additional costs that
would be incurred when undertaking an MSAT cam-
paign, based on new resources that would need to be
used to deliver the intervention. When spare capacity in
the health system exists, the use of that spare capacity is
not included in the marginal analysis. By contrast, the
average cost includes all those costs involved in deliver-
ing a health intervention, whether resources are shifted
away from other activities, or whether spare capacity is
used. In a generalized costing, an average cost analysis is
problematic, as countries differ in their level of infra-
structure, structure of the health system and capacity
use. Therefore, other than the two starting points con-
sidered (with (situation 1) and without (situation 2) anexisting network of CHWs), only the marginal interven-
tion cost was estimated.
Based on a literature review of similar interventions,
costs included in the estimate were household enumer-
ation, social mobilization, delivery (comprising volunteer
or CHW remuneration and supplies), training and super-
vision of village volunteers or CHWs. For the delivery,
training and supervision costs, an ingredients approach
was used, which involved building up a cost estimate by
considering the quantity and value of each resource used.
For the other costs, per-person costs were borrowed from
similar interventions described in the literature.
Systems costs from the district level upwards and in
health facilities were not included. A functioning health
system was assumed to be able to accommodate an an-
nual MSAT intervention without hiring additional staff
or making further investments at these levels. Clearly, if
the health system were poor, further investments might
be needed in order for MSAT to be successful, and this
could greatly increase the costs.
In this analysis, costing was conducted from a provider
perspective. It was assumed that there were no direct
costs to individuals and that indirect costs were negli-
gible, since the intervention was infrequent and con-
ducted at individuals’ homes.
Some of the costs presented here are relatively fixed
and thus sensitive to the scale at which the interven-
tion is conducted. For example, the average costs of a
sensitization campaign would likely decrease as more
people are included in the target population. However,
for the MSAT intervention, most of the costs are vari-
able and significant economies of scale are unlikely.
Therefore, economies and diseconomies of scale were
not explicitly considered in this analysis.
The intervention was undertaken over a period of six
days, with the first five days for initial visits and one
additional day for return visits to cover those not found
at the first visit. During initial visits, each team, which
consisted of three volunteers or CHWs, could complete
on average one household visit per hour, at an average
household size of five people [31]. This included time
for administering a questionnaire, conducting RDTs,
waiting for the results, and prescribing ACT to any who
tested positive. At this rate, eight household visits could
be done in a day during initial visits (assumption 1),
allowing five teams to cover a population of 1,000 in a
five-day period if every member of the population were
present during the first (and only) visits. The first drug
dose was assumed to be taken under supervision by the
CHW, and the remaining doses were left with the
households to be taken without supervision.
In the absence of data relating coverage to number of
follow-up visits, 40% of target households were assumed
to have at least one member absent on the first visit, with
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member missing. A repeat visit was thus required to 40%
of the households. Fifty percent of members missing on
the first visit were assumed to be found on the second
visit. Return visits were assumed to take half the time, as
some of the houses would already have been screened and
there would be fewer people to screen and treat. Thus, five
teams would be needed for the second visits to achieve ap-
proximately 85% population coverage.
Nv, the number of volunteers or CHWs needed, is
dependent upon factors like the population density, in-
frastructure, and the time it takes for a household visit.
Therefore, an alternative, assumption 2, was considered,
where only five household visits could be accomplished
in a day during initial visits. In this case, eight teams
would be required for the first and second visits.
Per diems were assumed to be given to volunteers or
CHWs as incentives and to cover transport. The role of
incentives in improving performance and encouraging
sustainability of interventions is a subject of debate; in a
number of settings, interventions relying on community
volunteers have suffered from a lack of financial and
non-financial support [32]. Salaries that may be paid to
CHWs for performing their roles were not included as
this was not considered an incremental cost incurred by
the MSAT intervention.
Each supervisor was assumed to be able to supervise
three volunteer or CHW teams and received per diems
according to the length of the intervention. Training
costs in situation 1 comprised only the cost of an add-
itional training on using and interpreting RDTs, while in
situation 2, volunteers needed to be recruited and
trained in all aspects of the intervention.
All costs were converted to 2007 US$, using the US$
average market exchange rate in the study year and the
US$ GDP deflator for the appropriate year [33].
The total cost per person screened per MSAT campaign
was approximately 2007 US$5–11, depending on different
health system scenarios and assumptions about the num-
ber of houses that could be visited per day. These costs
were added to the age-dependent ACT treatment costs,
for those that tested positive, to arrive at a total MSAT
intervention cost, presented in Table 1.
The model for the cost of MSAT is separate from the
epidemiological and case management models. Case
management coverage may be higher where a network
of trained CHWs exists. However, in this analysis the
MSAT cost model was used to develop a plausible range
for MSAT cost, and these costs were applied to all the
health system scenarios. Clinical cases were costed as
treated in health facilities using the case management
model [21], and the proportion of episodes treated in fa-
cilities was presumed unaffected.Incremental cost effectiveness ratio
The health care costs for malaria episodes were calcu-
lated for each intervention scenario and its comparator,
where MSAT was omitted. The case management cost
inputs are described in detail elsewhere [21], and were
updated with the costs of an ACT, artemether-lumefantrine
(AL), as first line treatment for uncomplicated malaria
[34]. Case management costs included direct costs for
patient care, but not patient indirect costs (notably loss
of productive time due to illness) since inclusion of
these in cost-effectiveness analysis remains controver-
sial and methods for valuing them vary widely [35].
The cost savings to the case management system asso-
ciated with adding MSAT to the comparator scenario
were computed as DCcmnoMSAT – DCcmMSAT, where
DCcmnoMSAT are the direct costs of case management in
the scenario without MSAT and DCcmMSAT are the dir-
ect costs of case management in the case of MSAT.
These cost savings were subtracted from the direct
MSAT intervention cost, DCMSAT, to give a net MSAT
intervention cost, NCMSAT, computed as follows: NCMSAT =
DCMSAT–(DCcmnoMSAT–DCcmMSAT). The savings to the
case management system constituted only the marginal cost
of averted cases, and fixed costs remained constant.
Table 2 shows the determinants of total health system
costs in each scenario. ITN costs were fixed per person
costs, assuming single occupancy, and therefore were
determined only by the ITN coverage level in the popu-
lation. MSAT costs constituted primarily the fixed cost
of screening individuals, but also depended on patent
parasitaemia prevalence in the population, which in turn
was driven by the vectorial capacity and ITN and case
management coverage levels. Case management costs
were a function of the health system use by the population
(case management coverage) as well as the disease burden,
which was determined by the vectorial capacity, ITN
coverage, MSAT coverage and case management coverage
itself (through its effect on recurrences and transmission).
The net intervention effects were expressed as the
number of episodes averted, i.e., the difference in the
number of episodes between intervention and compara-
tor scenarios. An incremental cost-effectiveness ratio
(ICER), expressed as dollars per case averted, was calcu-
lated for each scenario with MSAT compared to the
same scenario without MSAT, as the net cost (NC) of
the intervention divided by the net effects (NE) of the
intervention: ICERMSAT = NCMSAT/NEMSAT. If the ICER
is lower, the intervention is more attractive.
The ICER value is sensitive to the time horizon over
which it is calculated [36]. Therefore, to investigate how
the ICER changed over the time period of the interven-
tion, an annual ICER was calculated for each year of the
intervention as ICERMSATn =NCMSATn/NEMSATn, where
Table 1 Estimated costs per person screened by cost category and ACT costs by age group
Screening cost category Costs per person screened (2007 US$)
Household enumeration (Ep) 0.29
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intervention starts.
The cost-effectiveness of scaling up case management
coverage or ITN coverage from a given level to one level
higher was assessed in each health system, in the absence
of MSAT. The objective of this analysis was to compare,
roughly, the relative cost-effectiveness of undertaking one
or another intervention, in different settings. Cost per
ITN distributed was set as US$7, which is similar to the
US$7.03 median financial cost per ITN distributed
reported in a recent cost and cost-effectiveness review ofTable 2 Determinants of intervention costs
Intervention cost
category ITN coverage MSAT
ITN X
MSAT X X
Case management X Xmalaria control interventions [37]. Case management
costs were as previously described; fixed infrastructure
costs remained constant and scale-up costs included only
the marginal costs of treating additional cases.
Costs and effects were both discounted at an annual
rate of 3% in the analysis [38]. The practice of discount-
ing adjusts the value of future costs and effects to a
present value, according to the timing at which they are
incurred or occur. This is done to reflect the individual
and societal preference to have resources and money
now rather than in the future [39].Determinant of cost
Case management coverage Vectorial capacity
X X
X X
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Figure 1 illustrates how all-age parasite prevalence evolved
in a selected scenario. In this scenario, the pre-intervention
EIR was 20 IBPAPA, case management coverage was 20%
and ITN coverage was 40% at each distribution round.
Prevalence began to decrease after the first ITN distribu-
tion, dropped considerably after the first MSAT round,
and reached near zero by the fifth MSAT round. However,
it returned to and exceeded pre-intervention levels about
three years after all interventions were discontinued; the
higher post-intervention prevalence is due to reduced im-
munity in the population. Prevalence never reached zero
in any of the simulations, even during the time when
MSAT was conducted. An analysis of the probability of
interruption of transmission is outside the scope of this
paper.
In Figure 2, the average number of episodes averted by
MSAT is plotted against the average number of episodes
per 1,000 population per year in the comparator sce-
nario, for each factorial combination over the interven-
tion time period. The number of episodes in the all age
population in the comparator scenario with no ITNs or
case management was greatest at the intermediate trans-
mission level (EIR of 20 IBPAPA). Although infection
prevalence increased with increasing transmission over
almost all of the age range, the incidence of acute malaria
attacks in older children and adults was substantially
greater at low transmission levels than at higher ones.
This is because immunity levels rise with increasing trans-
mission, so a smaller proportion of infections are symp-
tomatic than at lower transmission levels. Therefore,
reductions in transmission may actually lead to an in-
creased incidence of disease due to P. falciparum [14].
The three panels combined show a bell-shaped curve;




















Figure 1 Median all-age parasite prevalence over the simulation perio
transmission in years 5–12, at a pre-intervention EIR of 20 IBPAPA, case ma
population per annum, and ITN coverage of 40%. Circles indicate ITN distriepisodes in the comparator was intermediate. This level
was reached with different combinations of interventions
at each pre-intervention EIR. At a pre-intervention EIR of
two IBPAPA, MSAT averted the most episodes when the
coverage of the other interventions, ITN and case manage-
ment, was zero. As case management coverage increased,
MSATaverted fewer episodes since transmission was lower
and some episodes had already been averted by case man-
agement. With any non-zero level of ITN coverage, trans-
mission was so low that there was essentially no disease for
MSAT to avert. At pre-intervention EIRs of 20 and 50
IBPAPA, the number of episodes averted by MSAT was
maximized at ITN coverage of 40% and 80% in each distri-
bution round, respectively, without case management.
These levels of ITN coverage reduced transmission suffi-
ciently to allow MSAT to have a sustained effect. MSAT
was more effective if this optimal transmission level was
reached via ITNs rather than case management because
MSAT and ITNs have different modes of action and thus
complement rather than duplicate each other. Without
ITNs, vectorial capacity remained high and individuals be-
came re-infected very soon after treatment with MSAT,
limiting the intervention’s effectiveness.
The natural logarithm of the ICER for adding MSAT
to scenarios with varying levels of case management and
ITN coverage at different pre-intervention EIRs is shown
in Figure 3. The average ICER over the 10 seeds for each
factorial combination is plotted against the average num-
ber of episodes in the comparator scenario over the
same time period. This figure suggests that MSAT was
most cost-effective in settings with a moderate disease
burden. At a pre-intervention EIR of two IBPAPA, this
level of disease burden was achieved without case man-
agement and ITNs. MSAT was least cost-effective where
case management and ITN coverage were at their10 12 14 16 18 20
 start of simulation
d. MSAT was conducted annually one month before the trough of
nagement coverage of 20%, two imported infections per 1,000
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Figure 2 Number of episodes averted as a function of number of episodes in the comparator scenario. Number of episodes averted per
1,000 population per year over the eight years of the MSAT campaigns are plotted against the number of episodes in the comparator scenario over
the same time period, for each factorial combination averaged over 10 unique seeds. Colours indicate levels of case management coverage: Yellow:
0%, Pink: 20%, Blue: 35%, Black: 55%. Plotting characters indicate levels of ITN coverage: Squares: 0%, Stars: 40%, Circles: 60%, Triangles: 80%.
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EIR of 20 IBPAPA occurred where ITN coverage was 40%
at each distribution round, and the number of episodes
was approximately 700 per 1,000 population per year. At
the highest pre-intervention EIR, 50 IBPAPA, the lowest
(best) ICER was achieved where case management and
ITN coverage levels were at or near their maximum, and
the disease burden level was similar to that of the best-
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Figure 3 Logarithm of MSAT ICER as a function of number of episode
an annual rate of 3% and aggregated over the eight years of the MSAT cam
the MSAT ICER was plotted against the number of episodes in the compar
averaged over 10 unique seeds. Colours indicate levels of case manageme
characters indicate levels of ITN coverage: Squares: 0%, Stars: 40%, Circles: 6settings. MSAT was never costsaving in any of these
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Figure 3 is a close, inverted, reflection of Figure 2, dem-
onstrating that the variation in ICER was driven in large
part by the variation in net effects of the intervention.
However, the ICER considers, in addition to the net
effects, its net costs, or the difference between the MSAT
intervention costs and the case management savings due
to the intervention. In some scenarios, particularly at the1000 1500
20
0 500 1000 1500
50
p. per year in the comparator scenario
l inoculation rate
s in the comparator scenario. Costs and effects were discounted at
paigns, using the US$7 MSAT cost estimate. The natural logarithm of
ator scenario over the same time period, for each factorial combination
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0%, Triangles: 80%.
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reduced the net effects of MSAT but also its net costs, so
the difference in ICERs was smaller than the difference in
net effects. Thus, the curves of ICERs in Figure 3 are less
linear than those representing numbers of episodes
averted in Figure 2.
Figure 4 illustrates the average ICER in each year from
the start to the end of the intervention, for each health
system and transmission setting. At a pre-intervention
EIR of two IBPAPA, with no ITNs and the lowest three
case management coverage levels, the ICER showed a
decreasing trend, indicating that the intervention be-
came more cost-effective over time. The same was true
at a pre-intervention EIR of 20 IBPAPA and ITN cover-
age of 40 to 80%, and at a pre-intervention EIR of 50
IBPAPA with ITN coverage of 80%. The opposite was
observed in the other scenarios; at an EIR of 50 IBPAPA
and without ITNs and case management, there were ac-
tually more episodes in scenarios with MSAT than in
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Figure 4 Logarithm of MSAT ICER in each year of the intervention. Th
US$7 MSAT cost estimate and averaged over 10 unique seeds, in different
management coverage: Yellow: 0%, Pink: 20%, Blue: 35%, Black: 55%.a negative ICER (not plotted), and suggests that under
these circumstances, doing MSAT would be more costly
and less effective than not doing it. This is probably be-
cause MSAT interfered with acquired immunity in this
fairly high transmission setting. The bumps in the curves
observed in scenarios with ITNs are due to reductions
in the number of episodes averted by MSAT in years 3
and 6 of the intervention, with ITNs distributed several
months before. As in Figure 3, the net effects of the
intervention were the main driver of the year-to-year
variation in the ICER, including their effects on case
management costs.
Table 3 compares the ICERs for the three interventions
undertaken separately in each baseline health system set-
ting, using high and low estimates for the per-person cost
of the MSAT screening component (see Additional file 1).
At a pre-intervention EIR of two IBPAPA MSAT was
never the most cost-effective intervention. Increasing ITN
coverage from 0 to 40% appeared to be the most cost-
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From a baseline of 40% ITN coverage and above, scaling
up case management coverage was the most cost-effective
option and, as expected, the MSAT ICERs became very
large.
At a pre-intervention EIR of 20 IBPAPA, scaling up
ITN coverage to the next level was the most cost-
effective intervention in settings of 0 and 40% ITN
coverage. At 60% ITN coverage, scaling up case manage-
ment coverage became the most cost-effective interven-
tion. However, at 40% ITN coverage, the MSAT ICER
was in a similar range to that of scaling up ITN and case
management coverage. At a pre-intervention EIR of 50
IBPAPA, the ICERs of scaling up ITN coverage from 0
or 40% were the lowest. Interestingly, at an ITN cover-
age of 60%, MSAT was similarly cost-effective to scaling
up ITN coverage further.Discussion
To date, MSAT for malaria has been considered almost
exclusively as an intervention to interrupt local trans-
mission of the parasite, or as a response to an epidemic
in a previously malaria-free area. Even if MSAT does not
result in sustained interruption of transmission, it may
be a cost-effective strategy to reduce the malaria burden
in some areas that are pursuing disease control. If usedTable 3 Incremental cost-effectiveness ratio (ICER) for differe
Baseline interventions Ann
2
CM coverage (%) ITN coverage (%) MSAT 11$ MSAT 5$ CM ITN
0 0 9.5 4.3 2.9 0.9
20 0 12.4 4.7 1.0 −0.3
35 0 18.0 6.7 −0.6 −0.8
55 0 34.4 13.6 – −0.8
0 40 523.6 238.0 2.3 22.8
20 40 1932.3 877.4 2.4 41.3
35 40 3276.3 1487.8 2.8 51.2
55 40 4668.5 2120.1 – 61.6
0 60 1817.6 826.3 2.9 76.7
20 60 5496.8 2497.7 2.9 120.8
35 60 7654.3 3477.7 3.8 153.7
55 60 11003.4 4999.7 – 178.4
0 80 3565.8 1620.9 3.1 –
20 80 9669.7 4394.5 4.0 –
35 80 14505.9 6592.2 4.6 –
55 80 17126.3 7782.7 – –
Comparison of ICERs of conducting MSAT with ICERs of increasing case manageme
columns), at different pre-intervention EIRs. ICERs for case management and ITNs re
level, holding coverage of the other intervention constant. Negative ICERs indicate
costs. Bold figures represent settings where MSAT may have comparable or lower Iin this way, MSAT should be continued indefinitely,
similar to ITN distribution.
Where prevalence is very low, infections are more likely
to be symptomatic and thus detected by the passive case
management system. The addition of mass treatment,
therefore, will probably not have a large effect on the inci-
dence of disease, particularly where case management
coverage is high. Where prevalence is high, a greater popu-
lation proportion will harbour asymptomatic infections, in-
creasing the effectiveness of mass treatment relative to
passive case detection. However, under these circum-
stances, individuals may become re-infected very soon after
treatment through MDA or MSAT, limiting the interven-
tion impact in averting disease. Of course, the effectiveness
will also depend on characteristics of the intervention itself,
such as the frequency with which it is carried out, popula-
tion coverage and compliance to diagnostic tests and treat-
ment regimens.
These results suggest that, in all the transmission settings
considered, achieving a minimal level of ITN coverage is al-
ways a “best buy”, and in low transmission settings, MSAT
is probably never worth considering for burden reduction
from a cost-effectiveness perspective. This finding is in
contrast to the current focus on MSAT as an intervention
for low transmission or near-elimination settings. Instead,
MSAT may be more suitable at medium to high transmis-
sion levels and at moderate ITN coverage. In these settings,nt interventions
ual EIR in the absence of interventions
20 50
MSAT 11$ MSAT 5$ CM ITN MSAT 11$ MSAT 5$ CM ITN
56.3 26.6 11.2 2.8 177.1 84.1 14.9 7.0
42.0 19.2 15.3 1.3 105.2 49.3 22.1 4.1
37.3 16.5 22.2 0.4 91.0 42.1 39.2 2.9
33.1 13.9 – −0.6 78.4 35.6 – 1.7
12.5 5.7 5.0 5.1 30.9 14.4 7.6 11.7
12.5 4.9 5.8 3.6 25.0 10.9 10.0 8.8
12.9 4.6 5.9 2.8 22.5 9.3 13.5 7.5
13.6 4.4 – 1.9 19.9 7.6 – 6.2
14.1 6.4 3.0 6.0 17.7 8.1 5.7 12.3
20.0 8.2 2.6 6.2 15.4 6.3 6.9 9.8
25.4 10.2 2.2 6.8 14.2 5.3 8.4 8.8
34.2 13.8 – 7.8 13.3 4.4 – 7.4
27.7 12.6 2.0 – 13.4 6.1 4.1 –
68.3 30.2 2.1 – 14.1 5.6 4.6 –
111.7 49.5 2.9 – 14.8 5.5 4.2 –
165.6 73.5 – – 16.0 5.5 – –
nt or ITN coverage in different baseline health system settings (two leftmost
fer to scaling up coverage from the baseline to the next highest coverage
that the intervention is costsaving due to reductions in case management
CERs to either scaling up ITNs or case management coverage to the next level.
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of scaling up case management and ITN coverage.
An interesting finding from this preliminary analysis,
and one that merits further investigation, is that achiev-
ing 80% ITN coverage across all settings, as per current
global malaria strategies [40], may not be an efficient use
of resources, particularly in low-transmission settings.
Given stagnating donor funding for malaria, and the fact
that ITNs account for the largest share of most malaria
programme expenditure [41], this finding may be im-
portant for malaria programme managers’ decisions.
The judgment as to whether or not an intervention is
cost-effective rests upon the decision maker’s valuation
of a unit of health gain, or the ceiling ratio. Values used
in practice are usually quoted per disability-adjusted life-
year (DALY) averted, and are based on affordability
expectations (such as $US150 per DALY), some multiple
of gross national income or gross domestic product, or
preference-elicitation methods [42]. This study’s results,
presented in 2007 $US per episode averted, do not refer
to a ceiling ratio and thus do not allow assessment of
whether MSAT is cost-effective or not. Rather, they pro-
vide an initial indication of the conditions under which
this strategy may be worth pursuing.
The effects of correlations in intervention coverage,
either between repeat distributions of the same interven-
tion or between receiving MSAT, ITNs and case man-
agement, have not been analysed. In principle such
correlations may result in either under- or overesti-
mation of the effects of the interventions. Positive cor-
relation between interventions is similar to adding new
interventions preferentially into population subgroups
with relatively high pre-existing coverage. This may be
efficient when effectiveness is greater at low transmis-
sion, but in general might be expected to make the inter-
vention package overall less cost-effective.
The estimate of the cost-effectiveness of MSAT relies
on the per-person cost of the intervention, which was
estimated from secondary data on costs for similar inter-
ventions. To account for this uncertainty, a high and a
low cost estimate were used. All campaign costs in-
curred were attributed to the MSAT intervention. How-
ever, MSAT could be more cost-effective if delivered
jointly with other interventions, since household visits
constitute most of the intervention costs. Notably, the
MDA costs for neglected tropical diseases have been
shown to be reduced where programmes are integrated
in places where diseases co-exist [43] and evidence sug-
gests this integration can be effective [44]. An ITN dis-
tribution programme was successfully integrated with
MDA for lymphatic filariasis and onchocerciasis in Cen-
tral Nigeria [45]. Also, costs per person screened were
assumed constant and incentives to community health
workers were included; this cost might vary dependingon the implementation stage, the use of volunteers, or
the programme scale [46].
On the other hand, achieving good MSAT implemen-
tation may incur costs that were not considered in the
cost estimate and presupposes a fairly strong health sys-
tem capable of organizing such an endeavour; otherwise,
control programmes for other diseases may suffer. In
this analysis, MSAT population coverage in each round
was assumed to be 85% and compliance to be perfect. A
well-conducted MSAT campaign will require careful
planning, social mobilization, community involvement,
and improvement of health care infrastructure, as was
documented in Vanuatu [47]. This is not trivial; for ex-
ample, the difficulties of maintaining an effective census
record in a past MDA campaign in Tanzania have been
described [48]. While achieving these high levels of
MSAT compliance and coverage may be challenging, the
aim of this study was to predict the cost-effectiveness of
the intervention under optimal conditions; future ana-
lyses could explore the sensitivity of ICERs to reduced
coverage and compliance.
The estimate of cost savings from averted case manage-
ment due to MSAT comprised only the marginal costs,
assuming that the fixed costs remained unchanged. How-
ever, a much lower malaria burden may free up capacity
for other interventions, boosting the cost-effectiveness of
MSAT. If this spare capacity can be used, it could have
significant benefits for the control of other diseases.
In these simulations, MSAT was conducted using exist-
ing diagnostic and pharmaceutical tools. Microscopy and
the current generation of RDTs fail to detect many low-
density infections, thus a number of sub-patent infections
is missed. More sensitive diagnostic tools appropriate for
use in the field are a target for future development [49],
and if these become available, the MSAT impact could be
enhanced. There could be benefits of other drug regimens,
for example adding primaquine (PQ) to ACT regimens,
which would make MDA/MSAT more effective in redu-
cing transmission [50], although a recent study found that
addition of PQ to ACT did not improve elimination of
parasitaemia and prevention of gametocyte carriage in
carriers with low-density parasitaemia in the dry season in
Sudan [51].
As in the case of MSAT, economies or dis-economies of
scale were not considered in the costs of scaling up case
management and ITN coverage. The model for the costs
of scaling up case management coverage does not account
for investments in infrastructure that would need to be
made when increasing coverage. In reality, scaling up case
management may be more costly than it appears in this
analysis. Moreover, a single estimate of distribution cost
per ITN (with single occupancy) was used; these vary de-
pending on scale, mode of distribution and other factors
[52]. This analysis could be extended by varying unit costs
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results. Also, if each ITN were assumed to cover more
than one person, the cost-effectiveness of ITNs would
increase.
In addition, the model used for ITNs, where the killing
effect of the net decayed exponentially with a half-life of
2.64 years, is quite simple. Estimating the cost-effectiveness
of ITNs and case management was not this paper’s focus,
and it aimed only to compare ICERs in orders of magni-
tude. Understanding of the cost-effectiveness of ITNs and
case management relative to each other and to other
interventions could be improved using more complex
models; one such model for ITNs is currently being deve-
loped [53].
The comparison of MSAT ICERs with those of scaling
up ITN and case management coverage should not be
construed as pitting the interventions against one an-
other, as combinations of the interventions may well be
an appropriate strategy. Improvements in case manage-
ment, in particular, represent investments in the wider
health system; they are valuable on that basis alone and
cannot be directly compared with preventive interven-
tions such as ITNs and MSAT. Furthermore, the use of
episodes as the measure of effects resulted in a biased
ICER for case management relative to the other two
interventions. Case management’s impact was consid-
ered only in terms of reduced host infectivity (and thus
reductions in future transmission) and decreased recur-
rences of illness due to one infection. However, as a
curative intervention, the most important effect of case
management is to reduce severe disease and mortality,
and this was not captured in the ICER denominator pre-
sented here. Scaling up case management is thus likely
to appear much less cost-effective in this analysis than it
would be in reality. Future analyses comparing the cost-
effectiveness of case management with that of preventive
interventions should include both disability and deaths
averted (expressed in DALYs) as an outcome measure.
Conclusion
Mass screening and treatment (MSAT) for malaria may be
worth considering as a burden-reducing intervention in
certain areas that possess adequate resources and health
system capacity to implement it well. If undertaken, it
should be as a complement, and not a replacement, for
case management and vector control interventions, like
insecticide-treated nets (ITNs). Also, policy-makers and
planners should be prepared to continue it indefinitely,
until new interventions become available or other devel-
opments make local transmission interruption a real
possibility.
MSAT is at the high end of a case management con-
tinuum that goes from passive case detection, to screening
only febrile or clinically suspected malaria in a smallradius around a confirmed case, to screening all indivi-
duals at a large radius around a confirmed case, to MSAT
and mass drug administration (MDA). One or another of
these options may ultimately be a better use of resources
than MSAT. More data is needed to determine the most
cost-effective surveillance and response strategies in differ-
ent settings.
Additional file
Additional file 1: Estimating the cost of MSAT for malaria.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
VC conceived the study, prepared the cost estimate, performed the analyses,
and wrote the manuscript. OJTB advised on analyses and contributed to the
manuscript. DH wrote the code for the simulations and helped with
preliminary analyses. NC helped develop the study design and contributed
to the manuscript. NM and ADP helped with the analysis of the simulations.
TAS advised on study design and analyses and contributed to the
manuscript. All authors read and approved the final manuscript.
Acknowledgements
The valuable inputs provided by Melissa Penny, Allan Schapira and Fabrizio
Tediosi, the costing advice and data provided by Giovanfrancesco Ferrari,
and the assistance of Michael Tarantino in generating simulation outputs are
gratefully acknowledged. A large number of volunteers are thanked for
making their computers available via http://www.malariacontrol.net for the
simulations. Funding for this project was provided by the Bill and Melinda
Gates Foundation, grant number 39777.01 and OPP1032350.
Received: 15 October 2012 Accepted: 19 December 2012
Published: 3 January 2013
References
1. Kern SE, Tiono AB, Makanga M, Gbadoe AD, Premji ZG, Gaye O, Sagara I,
Ubben D, Cousin M, Oladiran F, Sander O, Ogutu B: Community screening
and treatment of asymptomatic carriers of Plasmodium falciparum with
artemether-lumefantrine to reduce malaria disease burden: a modelling
and simulation analysis. Malar J 2011, 10:210.
2. The malERA Consultative Group on Drugs: A research agenda for malaria
eradication: drugs. PLoS Med 2011, 8:e1000402.
3. Dondorp AM, Yeung S, White L, Nguon C, Day NP, Socheat D, von Seidlein
L: Artemisinin resistance: current status and scenarios for containment.
Nat Rev Microbiol 2010, 8:272–280.
4. von Seidlein L, Greenwood BM: Mass administrations of antimalarial
drugs. Trends Parasitol 2003, 19:452–460.
5. Griffin JT, Hollingsworth TD, Okell LC, Churcher TS, White M, Hinsley W,
Bousema T, Drakeley CJ, Ferguson NM, Basanez M, Ghani AC: Reducing
Plasmodium falciparum malaria transmission in Africa: a model-based
evaluation of intervention strategies. PLoS Med 2010, 7:e1000324.
6. Okell LC, Griffin JT, Kleinschmidt I, Hollingsworth TD, Churcher TS, White MJ,
Bousema T, Drakeley CJ, Ghani AC: The potential contribution of mass
treatment to the control of Plasmodium falciparum malaria. PLoS One
2011, 6:e20179.
7. Crowell V, Hardy D, Briet O, Chitnis N, Maire N, Smith T: Can we depend on
case management to prevent re-establishment of P. falciparum malaria,
after local interruption of transmission? Epidemics 2012, 4:1–8.
8. Wilson AL: A systematic review and meta-analysis of the efficacy and
safety of intermittent preventive treatment of malaria in children (IPTc).
PLoS One 2011, 6:e16976.
9. Aponte JJ, Schellenberg D, Egan A, Breckenridge A, Carneiro I, Critchley J,
Danquah I, Dodoo A, Kobbe R, Lell B, May J, Premji Z, Sanz S, Sevene E,
Soulaymani-Becheikh R, Winstanley P, Adjei S, Anemana S, Chandramohan
D, Issifou S, Mockenhaupt F, Owusu-Agyei S, Greenwood B, Grobusch MP,
Crowell et al. Malaria Journal 2013, 12:4 Page 13 of 14
http://www.malariajournal.com/content/12/1/4Kremsner PG, Macete E, Mshinda H, Newman RD, Slutsker L, Tanner M,
Alonso P, Menendez C: Efficacy and safety of intermittent preventive
treatment with sulfadoxine-pyrimethamine for malaria in African infants:
a pooled analysis of six randomised, placebo-controlled trials. Lancet
2009, 374:1533–1542.
10. Gosling RD, Okell L, Mosha J, Chandramohan D: The role of antimalarial
treatment in the elimination of malaria. Clin Microbiol Infect 2011,
17:1617–1623.
11. White NJ: The role of anti-malarial drugs in eliminating malaria. Malar J
2008, 7 Suppl 1:S8.
12. Smith T, Ross A, Maire N, Chitnis N, Studer A, Hardy D, Brooks A, Penny M,
Tanner M: Ensemble modeling of the likely public health impact of a
pre-erythrocytic malaria vaccine. PLoS Med 2012, 9:e1001157.
13. Maire N, Smith T, Ross A, Owusu-Agyei S, Dietz K, Molineaux L: A model for
natural immunity to asexual blood stages of Plasmodium falciparum
malaria in endemic areas. AmJTrop Med Hyg 2006, 75:19–31.
14. Smith T, Ross A, Maire N, Rogier C, Trape JF, Molineaux L: An epidemiologic
model of the incidence of acute illness in Plasmodium falciparum
malaria. AmJTrop Med Hyg 2006, 75:56–62.
15. Ross A, Maire N, Molineaux L, Smith T: An epidemiologic model of severe
morbidity and mortality caused by Plasmodium falciparum. AmJTrop Med
Hyg 2006, 75:63–73.
16. Chitnis N, Smith T, Steketee R: A mathematical model for the dynamics of
malaria in mosquitoes feeding on a heterogeneous host population. J
Biol Dyn 2008, 2:259–285.
17. Chitnis N, Hardy D, Smith T: A periodically-forced mathematical model for
the seasonal dynamics of malaria in mosquitoes. Bull Math Biol 2012,
74:1098–1124.
18. Smith T, Charlwood JD, Kihonda J, Mwankusye S, Billingsley P, Meuwissen J,
Lyimo E, Takken W, Teuscher T, Tanner M: Absence of seasonal variation in
malaria parasitaemia in an area of intense seasonal transmission. Acta
Trop 1993, 54:55–72.
19. Malaria Elimination Group: Malaria Elimination in Zanzibar: a Feasibility
Assessment; 2009.
20. Tatem AJ, Qiu Y, Smith DL, Sabot O, Ali AS, Moonen B: The use of mobile
phone data for the estimation of the travel patterns and imported
Plasmodium falciparum rates among Zanzibar residents. Malar J 2009,
8:287.
21. Tediosi F, Maire N, Smith T, Hutton G, Utzinger J, Ross A, Tanner M: An
approach to model the costs and effects of case management of
Plasmodium falciparum malaria in sub-Saharan Africa. AmJTrop Med Hyg
2006, 75:90–103.
22. Consultoria de Serviços e Pesquisas-COSEP Lda, Consultoria de Gestão e
Administração em Saúde-Consaúde Lda. [Angola], Macro International Inc:
Angola Malaria Indicator Survey 2006–07. Calverton, Maryland: COSEP Lda.,
Consaúde Lda., and Macro International Inc; 2007.
23. Tanzania Commission for AIDS, Zanzibar AIDS Commission, National Bureau
of Statistics, Office of the Chief Government Statistician, Macro International
Inc: Tanzania HIV/AIDS and Malaria Indicator Survey 2007–08. Dar es Salaam,
Tanzania: TACAIDS, ZAC, NBS, OCGS, and Macro International Inc; 2008.
24. Fogg C, Bajunirwe F, Piola P, Biraro S, Checchi F, Kiguli J, Namiiro P, Musabe
J, Kyomugisha A, Guthmann JP: Adherence to a six-dose regimen of
artemether-lumefantrine for treatment of uncomplicated Plasmodium
falciparum malaria in Uganda. AmJTrop Med Hyg 2004, 71:525–530.
25. Kokwaro G, Mwai L, Nzila A: Artemether/lumefantrine in the treatment of
uncomplicated falciparum malaria. Expert Opin Pharmacother 2007,
8:75–94.
26. Goodman C, Coleman P, Mills A: Economic analysis of malaria control in sub-
Saharan Africa. Geneva: Global Forum for Health Research; 2000.
27. McCombie SC: Treatment seeking for malaria: a review of recent
research. Soc Sci Med 1996, 43:933–945.
28. Ross A, Killeen G, Smith T: Relationships between host infectivity to
mosquitoes and asexual parasite density in Plasmodium falciparum.
AmJTrop Med Hyg 2006, 75:32–37.
29. von Seidlein L, Walraven G, Milligan PJ, Alexander N, Manneh F, Deen JL,
Coleman R, Jawara M, Lindsay SW, Drakeley C, De Martin S, Olliaro P,
Bennett S, Schim van der Loeff M, Okunoye K, Targett GA, McAdam KP,Doherty JF, Greenwood BM, Pinder M: The effect of mass administration
of sulfadoxine-pyrimethamine combined with artesunate on malaria
incidence: a double-blind, community-randomized, placebo-controlled
trial in The Gambia. Trans R Soc Trop Med Hyg 2003, 97:217–225.
30. INDEPTH Network: Population and Health in Developing Countries. Volume 1.
Population, Health and Survival at INDEPTH Sites. Ottawa, Ontario, Canada:
International Development Research Centre; 2002.
31. National Bureau of Statistics Tanzania and ICF Macro: Tanzania Demographic
and Health Survey 2010. Dar es Salaam, Tanzania: NBS and ICF Macro; 2011.
32. Bojang KA, Akor F, Conteh L, Webb E, Bittaye O, Conway DJ, Jasseh M,
Wiseman V, Milligan PJ, Greenwood B: Two strategies for the delivery of
IPTc in an area of seasonal malaria transmission in The Gambia: a
randomised controlled trial. PLoS Med 2011, 8:e1000409.
33. United States Department of Commerce Bureau of Economic Analysis:
[http://www.bea.gov/national/nipaweb/index.asp]
34. Tediosi F, Maire N, Penny M, Studer A, Smith TA: Simulation of the cost-
effectiveness of malaria vaccines. Malar J 2009, 8:127.
35. Chima RI, Goodman CA, Mills A: The economic impact of malaria in Africa:
a critical review of the evidence. Health Policy 2003, 63:17–36.
36. Ramsey S, Willke R, Briggs A, Brown R, Buxton M, Chawla A, Cook J, Glick H,
Liljas B, Petitti D, Reed S: Good research practices for cost-effectiveness
analysis alongside clinical trials: the ISPOR RCT-CEA Task Force report.
Value Health 2005, 8:521–533.
37. White MT, Conteh L, Cibulskis R, Ghani AC: Costs and cost-effectiveness of
malaria control interventions - a systematic review. Malar J 2011, 10:337.
38. Tan-Torres Edejer T, Baltussen R, Adam T, Hutubessy R, Acharya A, Evans DB,
Murray CJL (Eds): Making Choices in Health: WHO Guide to Cost-Effectiveness
Analysis. Geneva: World Health Organization; 2003.
39. Walker D, Kumaranayake L: Allowing for differential timing in cost
analyses: discounting and annualization. Health Policy Plan 2002,
17:112–118.
40. Partnership RBM: Global malaria action plan for a malaria-free world. Geneva:
Roll Back Malaria Partnership; 2008.
41. World Health Organization: World Malaria Report 2011. Geneva: World
Health Organization; 2011.
42. Shillcutt SD, Walker DG, Goodman CA, Mills AJ: Cost effectiveness in low-
and middle-income countries: a review of the debates surrounding
decision rules. PharmacoEconomics 2009, 27:903–917.
43. Conteh L, Engels T, Molyneux DH: Socioeconomic aspects of neglected
tropical diseases. Lancet 2010, 375:239–247.
44. Linehan M, Hanson C, Weaver A, Baker M, Kabore A, Zoerhoff KL, Sankara D,
Torres S, Ottesen EA: Integrated implementation of programs targeting
neglected tropical diseases through preventive chemotherapy: proving
the feasibility at national scale. AmJTrop Med Hyg 2011, 84:5–14.
45. Blackburn BG, Eigege A, Gotau H, Gerlong G, Miri E, Hawley WA, Mathieu E,
Richards F: Successful integration of insecticide-treated bed net
distribution with mass drug administration in Central Nigeria. AmJTrop
Med Hyg 2006, 75:650–655.
46. Goldman AS, Guisinger VH, Aikins M, Amarillo ML, Belizario VY, Garshong B,
Gyapong J, Kabali C, Kamal HA, Kanjilal S, Kyelem D, Lizardo J, Malecela M,
Mubyazi G, Nitiema PA, Ramzy RM, Streit TG, Wallace A, Brady MA,
Rheingans R, Ottesen EA, Haddix AC: National mass drug administration
costs for lymphatic filariasis elimination. PLoS Negl Trop Dis 2007, 1:e67.
47. Kaneko A, Taleo G, Kalkoa M, Yamar S, Kobayakawa T, Bjorkman A: Malaria
eradication on islands. Lancet 2000, 356:1560–1564.
48. Clyde DF: Mass administration of an antimalarial drug combining 4-
aminoquinoline and 8-aminoquinoline in Tanganyika. Bull World Health
Organ 1962, 27:203–212.
49. malERA Consultative Group on Diagnoses and Diagnostics: A research
agenda for malaria eradication: diagnoses and diagnostics. PLoS Med
2011, 8:e1000396.
50. Moonen B, Cohen JM, Snow RW, Slutsker L, Drakeley C, Smith DL,
Abeyasinghe RR, Rodriguez MH, Maharaj R, Tanner M, Targett G:
Operational strategies to achieve and maintain malaria elimination.
Lancet 2010, 376:1592–1603.
51. El-Sayed B, El-Zaki SE, Babiker H, Gadalla N, Ageep T, Mansour F, Baraka O,
Milligan P, Babiker A: A randomized open-label trial of artesunate-
Crowell et al. Malaria Journal 2013, 12:4 Page 14 of 14
http://www.malariajournal.com/content/12/1/4sulfadoxine-pyrimethamine with or without primaquine for elimination
of sub-microscopic P. falciparum parasitaemia and gametocyte carriage
in eastern Sudan. PLoS One 2007, 2:e1311.
52. Yukich JO, Lengeler C, Tediosi F, Brown N, Mulligan JA, Chavasse D, Stevens
W, Justino J, Conteh L, Maharaj R, Erskine M, Mueller DH, Wiseman V,
Ghebremeskel T, Zerom M, Goodman C, McGuire D, Urrutia JM, Sakho F,
Hanson K, Sharp B: Costs and consequences of large-scale vector control
for malaria. Malar J 2008, 7:258.
53. Briet OJ, Hardy D, Smith TA: Importance of factors determining the
effective lifetime of a mass, long-lasting, insecticidal net distribution:
a sensitivity analysis. Malar J 2012, 11:20.
doi:10.1186/1475-2875-12-4
Cite this article as: Crowell et al.: Modelling the cost-effectiveness of
mass screening and treatment for reducing Plasmodium falciparum
malaria burden. Malaria Journal 2013 12:4.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
